<DOC>
	<DOC>NCT00359840</DOC>
	<brief_summary>To assess the clinical effective dose of KRN321 administered with once triweekly schedule.</brief_summary>
	<brief_title>A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>patients diagnosed as solid tumor or malignant lymphoma patients receiving cyclic chemotherapy written informed consent hemoglobin concentration below 11 d/dL at enrollment life expectancy of more than 4 months hemolysis, gastrointestinal bleeding, postoperative bleeding iron deficiency megaloblastic anemia received &gt; 2 RBC transfusions within 4 weeks before randomization or any RBC transfusion within 2 weeks before randomization any primary hematological disorder that could cause anemia prior treatment with KRN321 received erythropoetin therapy within 8 weeks before treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>darbepoetin alfa</keyword>
	<keyword>anemia</keyword>
	<keyword>cancer patients</keyword>
	<keyword>chemotherapy</keyword>
</DOC>